Washington State Medical Oncology Society (WSMOS)

WSMOS Fall 2022 Membership Meeting Friday November 18, 2022, at the Cedarbrook Lodge near SeaTac WA

This meeting will be open to all Washington State oncology practices and institutions.
If you are interested in becoming a WSMOS member please email director@wsmosconference.org

Register now for the WSMOS Fall 2022 Membership Meeting​

START TIME

(All times PST)

TOPIC

7:30AM-8:15AM

Registration / Breakfast / Networking with Exhibitors

8:15AM-8:30AM

Welcome & Introductions – WSMOS Future

Presenters:

Blair Irwin, MD WSMOS President

Jay Lopez, MD WSMOS Incoming President 2022-2024

8:30AM-9:15AM

Overview of Value Based Care and EOM

Presenters:

Lalan Wilfong, MD – Vice President Payer Relations and Practice Transformation at McKesson

9:15AM-10:15AM

Enhancing Oncology Model Panel: Good & Bad: How physicians and practices succeed in providing equitable, high quality cancer care

Presenters:

Moderator: Sibel Blau, MD – CEO/President of QCCA & Exigent Research, Medical Director, NWMS

Panelist: Nikolas Buescher – Executive Director of Cancer Services Penn Medicine Lancaster General Health

Panelist: Lalan Wilfong, MD – Vice President Payer Relations and Practice Transformation at McKesson

10:15AM-10:45AM

Networking Break with Exhibitors

10:45AM-11:15AM

Next Generation Immunotherapies in Lymphoma

Presenters:

Krish Patel, MD – Director of Lymphoma, Program Director of Hematology and Cell Therapy, Swedish Cancer Institute Immunotherapy in Lymphoma

11:15AM-12:00PM

ROR1 Chimeric Antigen Receptor T Cell Therapy for NSCLC and Triple Negative Breast Cancer

Presenters:

Jennifer Specht, MD – Associate Professor, UW, Division of Medical Oncology; Associate Member, Fred Hutch, Clinical Research Division

12:00PM-1:00PM

University of Washington Fred Hutchinson Cancer Research Center Fellows Presentations:

Presenters:

Andrew Portuguese, MD – Transplantation for Myeloid Neoplasms with Antecedent Solid Tumor

Lisa Tachiki, MD – Extended Duration of Anti-PD-1 Therapy, Using Reduced Frequency Dosing, in Patients with Advanced Melanoma and Merkel Cell Carcinoma

Hiba Khan, MD, MPH – Rates of Germline Genetic Testing and DNA Damage Response Mutations Found Through Population-Based Recruitment of Men with Incident Metastatic Prostate Cancer

1:00PM-1:05PM

Heritage Grant Presentation

Presenters:

VIDEO

1:05PM-2:30PM

Lunch Networking Reception

2:30PM

Adjourn

Register now for the WSMOS Fall 2022 Membership Meeting

TIME

Friday November 18, 2022

7:30AM - 2:30PM

START TIME
All times PST

TOPIC

Presenters

7:30AM-8:15AM

Registration / Breakfast / Networking with Exhibitors

8:15AM-8:30AM

Welcome & Introductions – WSMOS Future

Blair Irwin, MD WSMOS President

Jay Lopez, MD WSMOS Incoming President 2022-2024

8:30AM-9:15AM

Overview of Value Based Care and EOM

Lalan Wilfond, MD – Vice President Payer Relations and Practice Transformation at McKesson

9:15AM-10:15AM

Enhancing Oncology Model Panel:Good & Bad: How physicians and practices succeed in providing equitable, high quality cancer care

Moderator:Sibel Blau, MD – CEO/President of QCCA & Exigent Research, Medical Director, NWMS

Panelist: Nikolas Buescher – Executive Director of Cancer Services Penn Medicine Lancaster General Health

Panelist: Lalan Wilfong, MD – Vice President Payer Relations and Practice Transformation at McKesson

10:15AM-10:45AM

Networking Break with Exhibitors

10:45AM-11:15AM

Next Generation Immunotherapies in Lymphoma

Krish Patel, MD – Director of Lymphoma, Program Director of Hematology and Cell Therapy, Swedish Cancer Institute Immunotherapy in Lymphoma

11:15AM-12:00PM

ROR1 Chimeric Antigen Receptor T Cell Therapy for NSCLC and Triple Negative Breast Cancer

Jennifer Specht, MD – Associate Professor, UW, Division of Medical Oncology; Associate Member, Fred Hutch, Clinical Research Division

12:00PM-1:00PM

University of Washington Fred Hutchinson Cancer Research CenterFellows Presentations:

Andrew Portuguese, MD – Transplantation for Myeloid Neoplasms with Antecedent Solid Tumor

Lisa Tachiki, MD – Extended Duration of Anti-PD-1 Therapy, Using Reduced Frequency Dosing, in Patients with Advanced Melanoma and Merkel Cell Carcinoma

Hiba Khan, MD, MPH – Rates of Germline Genetic Testing and DNA Damage Response Mutations Found Through Population-Based Recruitment of Men with Incident Metastatic Prostate Cancer

1:00PM-1:05PM

Heritage Grant Presentation

VIDEO

1:05PM-2:30PM

Lunch Networking Reception

2:30PM

Adjourn

Register now for the Washington State Medical Oncology Society (WSMOS) Virtual Spring 2022 Conference Series

Time

Thursday May 5, 2022

5:00pm - 8:20pm

5:00pm-6:15pm Please Visit with our Corporate Sponsors over at the Exhibit Hall!
Live Chat Rooms will be open during this time. Please feel free to visit the virtual ‘exhibit hall’ at any time today through Friday May 13th. We have over 30 exhibitors with lots of valuable resources and contact information for each company

Guest Speakers

6:15pm-6:30pm

Welcome & Introductions - Blair Irwin MD, MBA WSMOS President and Sibel Blau, MD WSMOS Board of Directors

6:30pm-7:10pm

The Evolution of MRD in Multiple Myeloma - Allison Jacob, Senior Medical Director for clonoSEQ at Adaptive Biotechnologies

7:10pm-7:50pm

Latest Updates on MRD Testing in the Clinical Setting - C. Ola Landgren, M.D., Ph.D. Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).

7:50pm-8:00pm

Q&A Panel - Allison Jacob and Dr. C. Ola Landgren

8:00pm-8:15pm

What the Heck Happened this Legislative Session!?! A Very Quick Legislative Update!

8:15-8:20

Q&A with Katie Kolan, JD

8:20pm-Adjourn.

Thanks for Attending! Stay tuned for info on Fall 2022.

We would like to encourage all of our Hematology and Oncology colleagues in the state of Washington, including Physicians, Fellows, Emeritus, Office Managers, Administrators, Pharmacists, NP’s, PA’s, and RN’s to have your voices heard. With your support, WSMOS will continue to be the leading professional organization for oncologists in the state of Washington and a resource for the oncology community through professional education, and information dissemination.

Membership is critical to the continued advancement of WSMOS interests:

  • To identify and work to improve oncology practice issues that adversely affect patient access to cancer care.
  • To act as a patient advocate to assure that patients have access to the best available care.
  • To support and encourage clinical research against cancer. To learn more about joining the WSMOS please contact us

Thursday May 5, 2022

Allison Jacob

Senior Medical Director for clonoSEQ at Adaptive Biotechnologies
Allison Jacob is the Senior Medical Director for clonoSEQ at Adaptive Biotechnologies, where she currently leads Medical Strategy and Evidence Generation across lymphoid malignancies. Since joining Adaptive in 2015, she has collaborated with numerous clinicians across over 100 clinical studies to advance the understanding of MRD in blood cancers. Prior to joining Adaptive, she spent 16 years at Immunex/Amgen in drug development. She received her Master of Science degree in Molecular and Cellular Biology from the University of Washington for research conducted at Fred Hutchison Cancer Research Center in Seattle, WA.

C. Ola Landgren, M.D., Ph.D.

Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).

Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.

He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.

Katie Kolan, JD

Kathryn Kolan Public Affairs
Katie Kolan, JD, has over a decade of experience in advocacy, lobbying, policy analysis, political strategy and coalition building. She has worked closely with the legislative and political process and state agencies. She has strong professional relationships with legislators, legislative staff, agencies and the community at-large. As part of her experience, she led the government affairs and policy team for the Washington State Medical Association.

Speakers - May 27, 2020

Andrew McKechnie

Named one of The Hill publications “Top Lobbyists” in D.C., Andrew McKechnie brings a wealth of public policy and political experience to Peck Madigan Jones. During his time on Capitol Hill, and as a consultant, Andrew has been a key player for over a decade on many of the major legislative and regulatory efforts impacting the health care sector.

Andrew previously served as policy advisor to Senator Chuck Grassley (R-IA) while he was the Senior Republican on the Senate Finance Committee. Prior to his work with Senator Grassley and the Senate Finance Committee, he served as a Legislative Assistant to former Senator Norm Coleman (R-MN) and former Rep. Jim Ramstad (R-MN), a senior member of the Ways and Means Committee. In addition to his legislative experience on Capitol Hill, Andrew has worked on Presidential, House and Senate campaigns.

With a strong background in health care policy, Andrew is a particularly valuable resource to clients trying to navigate and respond to the highly-regulated health care industry.

Andrew lives in D.C. with his wife and two children. In his free time, he is a competitive triathlete, completing four Ironman races.

Katie Kolan, JD

Katie Kolan – a native of NW Washington – led the government affairs and policy team for the Washington State Medical Association for a decade. Katie holds a J.D. from Golden Gate University School of Law. Katie got the lobbying ‘bug’ after working for a state senator and in legislative roles for Columbia Legal Services, a state agency, and in other legal capacities.

She has over a decade of experience in advocacy, coalition building and lobbying, and volunteer work in the community at-large. She’s interest and focus in healthcare and medical ethics issues, P&C insurance law, administrative law, end-of-life care, health insurance and medical business/industry development and technology. When she’s not working, she’s likely working out and also maintains an abiding interest in sci-fi, geeking out on politics and being out in the forest for days.

Moderator for the Conference

Jennie Crews, MD

Moderator on June 25, 2020

Blair Irwin, MD

Moderator on july 2, 2020

Jennie R. Crews, MD, MMM, FACP

Medical Director, SCCA Affiliate Network, Community Sites and Research Integration Seattle Cancer Care Alliance

Moderator on May 20, 2021 and May 27, 2021